Asco 2022 – Adicet works hard to avoid the allo Car-T scenario
Long-awaited gamma-delta Car-T data sees the response rate fall to 20% at six months, but when is a relapse not a relapse?
Asco 2022 – Carvykti casts a long shadow
Arcellx, Gracell and Oricell work hard to prove that there is still space for new Car-T therapies in multiple myeloma.
Sernova gets under the skin
The company believes its new combination technology can make insulin injections a thing of the past.
Iovance hammered as cell therapy disappoints
Lower – and shorter – efficacy add to serious doubts about the TIL therapy's future.
Nkarta: at least as good as Fate, at a tenth of the price
After a long wait, investors at last have early evidence that Nkarta’s Car-NK cells work – with a relatively clean safety profile to boot.
AACR 2022 – Biontech’s cell therapy effort bears fruit at last
But it’s still far too early to tell whether combining Car-T with an mRNA vaccine might improve response durability.
